参考资料:[1] U.S. FDA Approves Subcutaneous Administration ofTakeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately toSeverely Active Crohn’s Disease. Retrieved April 18, 2024 from https://www.takeda.com/newsroom/newsreleases/2024/fda-approves-subcutaneous-administration-of-entyvio/